

Saverio Minucci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/324628/publications.pdf>

Version: 2024-02-01

70
papers

15,350
citations

136950

32
h-index

95266

68
g-index

74
all docs

74
docs citations

74
times ranked

28805
citing authors

#	ARTICLE	IF	CITATIONS
1	Single cell-derived spheroids capture the self-renewing subpopulations of metastatic ovarian cancer. <i>Cell Death and Differentiation</i> , 2022, 29, 614-626.	11.2	20
2	Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AML. <i>Oncogene</i> , 2022, 41, 878-894.	5.9	17
3	SMARCA5 interacts with NUP98-NSD1 oncofusion protein and sustains hematopoietic cells transformation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 34.	8.6	14
4	Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 56, 116596.	3.0	8
5	Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models. <i>European Journal of Medicinal Chemistry</i> , 2022, 237, 114410.	5.5	15
6	Long non-coding RNA TINCR suppresses metastatic melanoma dissemination by preventing ATF4 translation. <i>EMBO Reports</i> , 2021, 22, e50852.	4.5	21
7	Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. <i>Clinical Cancer Research</i> , 2021, 27, 4311-4324.	7.0	44
8	Anticancer innovative therapy congress: Highlights from the 10th anniversary edition. <i>Cytokine and Growth Factor Reviews</i> , 2021, 59, 1-8.	7.2	4
9	Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. <i>Blood</i> , 2021, 137, 3093-3104.	1.4	91
10	Endosomal trafficking and DNA damage checkpoint kinases dictate survival to replication stress by regulating amino acid uptake and protein synthesis. <i>Developmental Cell</i> , 2021, 56, 2607-2622.e6.	7.0	6
11	Indolin-2-one derivatives as selective Aurora B kinase inhibitors targeting breast cancer. <i>Bioorganic Chemistry</i> , 2021, 117, 105451.	4.1	6
12	LSD1-directed therapy affects glioblastoma tumorigenicity by deregulating the protective ATF4-dependent integrated stress response. <i>Science Translational Medicine</i> , 2021, 13, eabf7036.	12.4	18
13	MicroRNA-222 Regulates Melanoma Plasticity. <i>Journal of Clinical Medicine</i> , 2020, 9, 2573.	2.4	10
14	Tuning mTORC1 activity dictates the response of acute myeloid leukemia to LSD1 inhibition. <i>Haematologica</i> , 2020, 105, 2105-2117.	3.5	20
15	Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid-induced differentiation. <i>Science Advances</i> , 2020, 6, eaax2746.	10.3	56
16	Comparing apples with oranges: Studying LSD1 inhibitors in cellular assays. <i>Pharmacological Research</i> , 2019, 146, 104345.	7.1	7
17	Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside. <i>European Journal of Cancer</i> , 2019, 122, 22-41.	2.8	7
18	Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3 ^β -MCL-1 Axis. <i>Cancer Cell</i> , 2019, 35, 798-815.e5.	16.8	212

#	ARTICLE	IF	CITATIONS
19	Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells. <i>European Journal of Medicinal Chemistry</i> , 2019, 165, 80-92.	5.5	34
20	Fumarate hydratase expression in localized, radically-resected clear cell renal cell carcinoma and its association with clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2019, 37, 620-620.	1.6	0
21	Extensive and systematic rewiring of histone post-translational modifications in cancer model systems. <i>Nucleic Acids Research</i> , 2018, 46, 3817-3832.	14.5	31
22	Epigenomic profiling of archived FFPE tissues by enhanced PAT-ChIP (EPAT-ChIP) technology. <i>Clinical Epigenetics</i> , 2018, 10, 143.	4.1	16
23	Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR/HER2 inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2018, 155, 316-336.	5.5	46
24	Prognostic and predictive role of fumarate hydratase in metastatic clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 617-617.	1.6	0
25	c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2542-2555.	7.0	105
26	The Role of Chromatin-Associated Proteins in Cancer. <i>Annual Review of Cancer Biology</i> , 2017, 1, 355-377.	4.5	10
27	Thieno[3,2- <i>b</i>]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 1: High-Throughput Screening and Preliminary Exploration. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1673-1692.	6.4	59
28	Thieno[3,2- <i>b</i>]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 2: Structure-Based Drug Design and Structure-Activity Relationship. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1693-1715.	6.4	60
29	Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 575-581.	3.3	17
30	Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors. <i>ACS Chemical Biology</i> , 2017, 12, 2491-2497.	3.4	28
31	Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. <i>Nature Communications</i> , 2017, 8, 593.	12.8	175
32	Entinostat for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 965-971.	4.1	54
33	Novel potent inhibitors of the histone demethylase KDM1A (LSD1), orally active in a murine promyelocytic leukemia model. <i>Future Medicinal Chemistry</i> , 2017, 9, 1161-1174.	2.3	4
34	A comprehensive review of lysine-specific demethylase 1 and its roles in cancer. <i>Epigenomics</i> , 2017, 9, 1123-1142.	2.1	125
35	From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib. <i>Frontiers in Pharmacology</i> , 2017, 8, 718.	3.5	23
36	Mass-spectrometry analysis of histone post-translational modifications in pathology tissue using the PAT-H-MS approach. <i>Data in Brief</i> , 2016, 7, 188-194.	1.0	6

#	ARTICLE	IF	CITATIONS
37	<i>In Vivo</i> Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype. <i>Cancer Discovery</i> , 2016, 6, 650-663.	9.4	59
38	Self-renewal of tumor cells: epigenetic determinants of the cancer stem cell phenotype. <i>Current Opinion in Genetics and Development</i> , 2016, 36, 92-99.	3.3	18
39	DNA binding modes of leukemia oncoproteins. <i>Blood</i> , 2016, 127, 177-178.	1.4	2
40	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
41	Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia. <i>British Journal of Cancer</i> , 2016, 114, 605-611.	6.4	210
42	Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1501-1517.	6.4	70
43	Synthesis, biological characterization and molecular modeling insights of spirochromanes as potent HDAC inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2016, 108, 53-67.	5.5	26
44	Pathology Tissue-quantitative Mass Spectrometry Analysis to Profile Histone Post-translational Modification Patterns in Patient Samples. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 866-877.	3.8	41
45	Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies. <i>Blood</i> , 2015, 126, 2392-2403.	1.4	48
46	Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer. <i>Antioxidants and Redox Signaling</i> , 2015, 23, 15-29.	5.4	13
47	Pure enantiomers of benzoylamino-tranylcypromine: LSD1 inhibition, gene modulation in human leukemia cells and effects on clonogenic potential of murine promyelocytic blasts. <i>European Journal of Medicinal Chemistry</i> , 2015, 94, 163-174.	5.5	28
48	Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: From bench to bedside. <i>Cancer Treatment Reviews</i> , 2015, 41, 754-760.	7.7	19
49	Tackling Oxidative Stress by a Direct Route: A New Job for HDAC Inhibitors?. <i>Chemistry and Biology</i> , 2015, 22, 431-432.	6.0	2
50	Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion. <i>Nature Communications</i> , 2015, 6, 10044.	12.8	108
51	Pure Diastereomers of a Tranylcypromine-Based LSD1 Inhibitor: Enzyme Selectivity and In-Cell Studies. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 173-177.	2.8	16
52	Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: A novel class of irreversible inhibitors of histone demethylase KDM1A. <i>European Journal of Medicinal Chemistry</i> , 2014, 86, 352-363.	5.5	50
53	Beclin 1 restrains tumorigenesis through Mcl-1 destabilization in an autophagy-independent reciprocal manner. <i>Nature Communications</i> , 2014, 5, 5637.	12.8	65
54	Functional characterization of a novel FGFR1OP→RET rearrangement in hematopoietic malignancies. <i>Molecular Oncology</i> , 2014, 8, 221-231.	4.6	27

#	ARTICLE	IF	CITATIONS
55	PAT-ChIP coupled with laser microdissection allows the study of chromatin in selected cell populations from paraffin-embedded patient samples. <i>Epigenetics and Chromatin</i> , 2014, 7, 18.	3.9	22
56	Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure. <i>Nature Medicine</i> , 2014, 20, 167-174.	30.7	166
57	Quantitative Chemical Proteomics Identifies Novel Targets of the Anti-cancer Multi-kinase Inhibitor E-3810. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 1495-1509.	3.8	14
58	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	9.1	3,122
59	HDACs link the DNA damage response, processing of double-strand breaks and autophagy. <i>Nature</i> , 2011, 471, 74-79.	27.8	368
60	Fish the ChIPs: a pipeline for automated genomic annotation of ChIP-Seq data. <i>Biology Direct</i> , 2011, 6, 51.	4.6	12
61	Biochemical, Structural, and Biological Evaluation of Tranylcypromine Derivatives as Inhibitors of Histone Demethylases LSD1 and LSD2. <i>Journal of the American Chemical Society</i> , 2010, 132, 6827-6833.	13.7	261
62	Epigenetic therapies in haematological malignancies: Searching for true targets. <i>European Journal of Cancer</i> , 2009, 45, 1137-1145.	2.8	45
63	Determinants of Oncogenic Transformation in Acute Promyelocytic Leukemia: The Hetero-Union Makes the Force. <i>Cancer Cell</i> , 2007, 12, 1-3.	16.8	11
64	Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. <i>Nature Reviews Cancer</i> , 2006, 6, 38-51.	28.4	2,049
65	PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. <i>Blood</i> , 2002, 100, 2989-2995.	1.4	103
66	Methyltransferase Recruitment and DNA Hypermethylation of Target Promoters by an Oncogenic Transcription Factor. <i>Science</i> , 2002, 295, 1079-1082.	12.6	754
67	Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?. <i>Oncogene</i> , 2001, 20, 3110-3115.	5.9	191
68	Common themes in the pathogenesis of acute myeloid leukemia. <i>Oncogene</i> , 2001, 20, 5680-5694.	5.9	72
69	Oligomerization of RAR and AML1 Transcription Factors as a Novel Mechanism of Oncogenic Activation. <i>Molecular Cell</i> , 2000, 5, 811-820.	9.7	273
70	Fusion proteins of the retinoic acid receptor- α recruit histone deacetylase in promyelocytic leukaemia. <i>Nature</i> , 1998, 391, 815-818.	27.8	1,015